Cargando…
HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533590/ https://www.ncbi.nlm.nih.gov/pubmed/31156634 http://dx.doi.org/10.3389/fimmu.2019.01081 |
_version_ | 1783421238935289856 |
---|---|
author | Couture, Alexandre Garnier, Anthony Docagne, Fabian Boyer, Olivier Vivien, Denis Le-Mauff, Brigitte Latouche, Jean-Baptiste Toutirais, Olivier |
author_facet | Couture, Alexandre Garnier, Anthony Docagne, Fabian Boyer, Olivier Vivien, Denis Le-Mauff, Brigitte Latouche, Jean-Baptiste Toutirais, Olivier |
author_sort | Couture, Alexandre |
collection | PubMed |
description | CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4(+) T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4(+) T cells. Here, we review the recent advances in understanding the functions of CD4(+) T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4(+) T cell responses and as reagents to generate clinical grade antigen-specific CD4(+) T cells for immunotherapy. |
format | Online Article Text |
id | pubmed-6533590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65335902019-05-31 HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy Couture, Alexandre Garnier, Anthony Docagne, Fabian Boyer, Olivier Vivien, Denis Le-Mauff, Brigitte Latouche, Jean-Baptiste Toutirais, Olivier Front Immunol Immunology CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4(+) T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4(+) T cells. Here, we review the recent advances in understanding the functions of CD4(+) T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4(+) T cell responses and as reagents to generate clinical grade antigen-specific CD4(+) T cells for immunotherapy. Frontiers Media S.A. 2019-05-17 /pmc/articles/PMC6533590/ /pubmed/31156634 http://dx.doi.org/10.3389/fimmu.2019.01081 Text en Copyright © 2019 Couture, Garnier, Docagne, Boyer, Vivien, Le-Mauff, Latouche and Toutirais. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Couture, Alexandre Garnier, Anthony Docagne, Fabian Boyer, Olivier Vivien, Denis Le-Mauff, Brigitte Latouche, Jean-Baptiste Toutirais, Olivier HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title | HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title_full | HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title_fullStr | HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title_full_unstemmed | HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title_short | HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy |
title_sort | hla-class ii artificial antigen presenting cells in cd4(+) t cell-based immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533590/ https://www.ncbi.nlm.nih.gov/pubmed/31156634 http://dx.doi.org/10.3389/fimmu.2019.01081 |
work_keys_str_mv | AT couturealexandre hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT garnieranthony hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT docagnefabian hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT boyerolivier hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT viviendenis hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT lemauffbrigitte hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT latouchejeanbaptiste hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT toutiraisolivier hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy |